National pharmacare – might it be a pig in a poke? Nigel Rawson and John Adams for Inside Policy
By Nigel Rawson and John Adams, May 28, 2024 No Canadian should have to choose between paying for medicines and ...
Tag: Pharmacare
Exposing 12 myths that support drug price controls and harm our health system
OTTAWA, ON (June 28, 2022): Is the Patented Medicine Prices Review Board (PMPRB) causing more harm than good? A recent ...
Timely access for patients to innovative medicines – A policy change overdue: Rawson and Adams for Inside Policy
By Nigel Rawson and John Adams, March 24, 2022 Much has been written over the last few years about the ...
Canadians will pay a heavy price as Ottawa cuts drug costs
A new MLI commentary warns that pending and aggressive drug price control efforts could lead to major unintended consequences in ...
False Premise – Federal Regulation of Drug Prices as a Step to National Pharmacare: Rawson and Adams in National Newswatch
Advocates for national pharmacare who insist on control of drug prices, not by negotiation but by federal regulation, may have ...
Quebec gets the constitution right (on drug price control): Richard Owens in the Financial Post
While unconstitutional institutions and policies may be accommodated by the provinces to some degree, pushing them too far will end ...
Drug prices can go too low: Richard C. Owens in the Financial Post
By determinedly reducing revenues Canada not only ensures the unavailability of existing medications, it sees to it that far fewer ...
COVID-19 Highlights Weaknesses in Canada’s System for New Medicines: MLI report by Rawson and Adams
OTTAWA, ON (June 18, 2020): The COVID-19 pandemic has revealed numerous weaknesses in Canadian health care, and as the world ...
MLI experts available to comment on delay to federal drug price reduction scheme
OTTAWA, ON (June 2, 2020): Changes to the Patented Medicine Prices Review Board (PMPRB) have been delayed until January 2021 ...
COVID-19, other rare disorders and the rescue principle: Nigel Rawson and John Adams for Inside Policy
Lower ceiling prices for new medicines will make Canada less attractive as a country for new drugs and vaccines, making ...
Video and photos – Is Donald Trump coming for Canadians’ medicines?
An old idea for a short-cut to cheaper medicines in the US seems to be gaining momentum in 2019. President ...
Canada’s New Rules Aiming to Cut Drug Prices May Penalize Consumers: Richard Owens in the Epoch Times
Price-focused regulatory changes could limit access to new drugs and dampen R&D investment, writes Richard Owens. By Richard C. Owens, ...
-
Mexican cartels are a direct threat to Canada’s public safety, and the future of North American trade: Gary J. Hale for Inside Policy
-
Canadians are very unhappy with the federal public service—and for good reason: Tim Sargent in The Hub
-
Unfortunately for Canadian consumers and creators, the Online Streaming Act is performing exactly as predicted: Peter Menzies in the Hub
-
Will Justin Trudeau prorogue Parliament in the new year? History shows there’s little political cost to the practice: Dave Snow in The Hub
-
Canada is an energy superpower. It’s time to remind America and act like it: Heather Exner-Pirot in The Hub
